Nina Melo

Nina Melo

Auto-generated profile, based on publicly available information

Nina Melo

Associação Brasileira de Talassemia - Abrasta. São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2020 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
DMDenise Pires Martins
Denise Pires Martins
NCNelson Francisco Correa-Netto
Nelson Francisco Correa-Netto
NMNina Melo
Nina Melo
SLSandra Regina Loggetto
Sandra Regina Loggetto
MLMárcia Mello Costa De Liberal
Márcia Mello Costa De Liberal
Knowing the information regarding the panorama of lymphoma diagnosis in patients treated in the Brazilian Public Unified Health System from the last 10 years is a challenge for Strategic Health Planning. To characterize the Brazilian population with lymphoma treated in the Brazilian Public Unified Health System between 2008 and 2017 regarding staging, sex, residence site and mortality. A descriptive, retrospective, and longitudinal trial with secondary data from DataSUS (SIA/SUS and SIM/SUS) obtained from patients with ICD-10 C81-85. There were 70,850 lymphoma cases between 2008 and 2017, of which 55% were male, the median age was 51 years, and 27% had Hodgkin Lymphoma. Most patients (56%) were treated outside the residence city. São Paulo State accounted for 25% of patients. Treatment initiation took more than 60 days in 27% of cases. A total of 45,601 deaths were due to lymphoma (12% Hodgkin Lymphoma and 88% Non-Hodgkin Lymphoma), with a median age 63 years, and were mainly males (55%). Staging data were inadequate in 23% of patients, and analysis was performed only on the valid records. Advanced disease was diagnosed in 58% of patients (60% male; 57% female) and was more common in Non-Hodgkin Lymphoma (62%) versus Hodgkin Lymphoma (49%). Late diagnosis interferes with mortality rates. Health promotion and cancer prevention campaigns, especially targeting the male public, and training for early diagnosis and early treatment are needed. Effective measures for early diagnosis and treatment are urgently needed for lymphoma control.

27 April 2026 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
RCRodolfo Delfini Cançado
Rodolfo Delfini Cançado
PCPaula de Melo Campos
Paula de Melo Campos
DKDiego Kashiura
Diego Kashiura
FTFelipe Thies
Felipe Thies
EFErica Ferreira
Erica Ferreira
ABAlessandro Bigoni
Alessandro Bigoni
Paroxysmal nocturnal hemoglobinuria is a rare, life-threatening disease that significantly affects quality of life. Despite therapeutic advances, challenges like treatment burden and limited care access persist. This study aimed to evaluate the geographic distribution of paroxysmal nocturnal hemoglobinuria patients in Brazil and explore how travel distance to treatment centers may influence treatment persistence. A mixed-methods study was conducted combining quantitative analysis of administrative claims data from the Brazilian Unified Health System and qualitative insights from patient focus groups. The quantitative component included patients with at least one ICD-10 D59.5 code between January 2010 and December 2023. The qualitative component involved a focus group of adult paroxysmal nocturnal hemoglobinuria patients registered with the Brazilian Lymphoma and Leukemia Association (ABRALE). Descriptive statistics were used to summarize demographic, geographic, and treatment-related data. A total of 769 patients were identified, with 42.4% receiving eculizumab. The mean time to treatment initiation was 172.9 days. Spatial analysis revealed substantial regional variations, with eculizumab-treated patients traveling an average of 87.5 km for care. Persistence analysis showed that 21.2% and 61.0% of patients were non-persistent based using two different methodological approaches. Focus group participants reported limited disease awareness, long travel distances, and extended waiting times, all of which negatively impacted their daily lives and treatment adherence. This study highlights geographic disparities in access to paroxysmal nocturnal hemoglobinuria treatment in Brazil and suggests that the travel burden may contribute to treatment non-persistence. These findings underscore the need for more accessible and patient-centered therapeutic options to promote equitable healthcare delivery.

2 May 2026 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
JGJanaína Rosenburg Gioseffi
Janaína Rosenburg Gioseffi
FSFernanda Cristina dos Santos Simão
Fernanda Cristina dos Santos Simão
NMNina Melo
Nina Melo
EFEduardo Maercio Fróes
Eduardo Maercio Fróes
TATalita Garrido Araújo
Talita Garrido Araújo
SLSandra Loggetto
Sandra Loggetto
To outline the sociodemographic and therapeutic profile of individuals with thalassemia in Brazil between 2012 and 2022, by analyzing data from the Ministry of Health on outpatient care, hospitalization, and mortality records. This descriptive, cross-sectional study utilized secondary data from the Outpatient, Hospital, and Mortality Information Systems of the Ministry of Health on patients diagnosed with thalassemia (ICD-10 D56). Analyzed variables included demographics (sex, age, race/ethnicity), geographic location (residence and treatment site), and clinical outcomes (procedures, hospitalizations, and deaths). In 2022, an estimated 662 patients received outpatient treatment in the Brazilian Unified Health System (SUS), with a predominance of young adults, women, and individuals self-identified as White, who were mostly concentrated in the southeastern and southern regions of the country. Red blood cell transfusion was the most frequently performed outpatient procedure during the period. There were 1278 hospitalizations, mainly of children aged 0-9 years. A total of 153 deaths were recorded, primarily among people aged 50 years or older. The findings characterize the patient profile, identify significant travel challenges to receive treatment, and suggest potential underreporting within reference institutions. It is essential to improve data recording in public databases to support specific health policies and ensure comprehensive, equitable, and continuous treatment for people living with thalassemia in Brazil.

20 May 2025 in Saúde Coletiva (Barueri)
Verified
Journal Article
Open access
PDF file
ASAna Carolina Gomes dos Santos
Ana Carolina Gomes dos Santos
AAAna Beatriz Machado de Almeida
Ana Beatriz Machado de Almeida
FSFernanda Cristina Santos Simão
Fernanda Cristina Santos Simão
NMNina Melo
Nina Melo
JGJanaína Rosenburg Gioseffi
Janaína Rosenburg Gioseffi
NHNelson Hamerschlak
Nelson Hamerschlak
OBJETIVO: Este estudo analisou dados sociodemográficos e o tratamento de pacientes portadores de mieloma múltiplo no Brasil, identificando impactos nos sistemas de saúde. MÉTODOS: Estudo descritivo por meio de questionário autopreenchido, enviado entre outubro de 2021 e janeiro de 2023 a pacientes cadastrados na Associação Brasileira de Linfoma e Leucemia (Abrale). RESULTADOS: Participaram 164 pacientes, dos quais 133 (81%) tinham sintomas antes do diagnóstico. A maioria (117; 71%) passou por duas ou mais consultas antes do hematologista. O tempo médio para diagnóstico foi maior no sistema público (178 dias) que no privado (128 dias), e 38% relataram dificuldades de acesso. O diagnóstico e tratamento impactaram a rotina de 138 (84%) pacientes. CONCLUSÃO: Os resultados reforçam a importância de mapear obstáculos para discutir melhorias no tratamento e garantir atendimento adequado a todos.